Expression pattern of cdkl5 during zebrafish early development: implications for use as model for atypical Rett syndrome
- 206 Downloads
Atypical Rett syndrome is a child neurodevelopmental disorder induced by mutations in CDKL5 gene and characterized by a progressive regression in development with loss of purposeful use of the hands, slowed brain and head growth, problems with walking, seizures, and intellectual disability. At the moment, there is no cure for this pathology and little information is available concerning animal models capable of mimicking its phenotypes, thus the development of additional animal models should be of interest to gain more knowledge about the disease. Zebrafish has been used successfully as model organism for many human genetic diseases; however, no information is available concerning the spatial and temporal expression of cdkl5 orthologous in this organism. In the present study, we identified the developmental expression patterns of cdkl5 in zebrafish by quantitative PCR and whole-mount in situ hybridization. cdkl5 is expressed maternally at low levels during the first 24 h of development. After that the expression of the gene increases significantly and it starts to be expressed mainly in the nervous system and in several brain structures, such as telencephalon, mesencephalon and diencephalon. The expression patterns of cdkl5 in zebrafish is in accordance with the tissues known to be affected in humans and associated to symptoms and deficits observed in Rett syndrome patients thus providing the first evidence that zebrafish could be an alternative model to study the molecular pathways of this disease as well as to test possible therapeutic approaches capable of rescuing the phenotype.
KeywordsCdkl5 Zebrafish Brain Rett syndrome
This research was partially supported by national funds from FCT - Foundation for Science and Technology through project UID/Multi/04326/2013. MV was supported by a postdoctoral fellowship reference SFRH/BPD/65923/2009 from the Portuguese Foundation for Science and Technology (FCT).
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
All experimental procedures involving animals followed the European Directive 2010/63/EU and the related guidelines (European Commission, 2014) and Portuguese legislation (Decreto-Lei 113/2013 and Despacho 2880/2015) for animal experimentation and welfare.
- 2.Wang ITJ, Allen M, Goffin D, Zhu X, Fairless AH, Brodkin ES, Siegel SJ, Marsh ED, Blendy JA, Zhou Z (2012) Loss of CDKL5 disrupts kinome profile and event-related potentials leading to autistic-like phenotypes in mice. Proc Natl Acad Sci USA 109(52):21516–21521. https://doi.org/10.1073/pnas.1216988110 CrossRefPubMedGoogle Scholar
- 3.Amendola E, Zhan Y, Mattucci C, Castroflorio E, Calcagno E, Fuchs C, Lonetti G, Silingardi D, Vyssotski AL, Farley D, Ciani E, Pizzorusso T, Giustetto M, Gross CT (2014) Mapping pathological phenotypes in a mouse model of CDKL5 disorder. PLoS ONE 9(5):e91613. https://doi.org/10.1371/journal.pone.0091613 CrossRefPubMedPubMedCentralGoogle Scholar
- 4.Okuda K, Kobayashi S, Fukaya M, Watanabe A, Murakami T, Hagiwara M, Sato T, Ueno H, Ogonuki N, Komano-Inoue S, Manabe H, Yamaguchi M, Ogura A, Asahara H, Sakagami H, Mizuguchi M, Manabe T, Tanaka T (2017) CDKL5 controls postsynaptic localization of GluN2B-containing NMDA receptors in the hippocampus and regulates seizure susceptibility. Neurobiol Dis 106(Supplement C):158–170. https://doi.org/10.1016/j.nbd.2017.07.002 CrossRefPubMedGoogle Scholar
- 7.Khan KM, Collier AD, Meshalkina DA, Kysil EV, Khatsko SL, Kolesnikova T, Morzherin YY, Warnick JE, Kalueff AV, Echevarria DJ (2017) Zebrafish models in neuropsychopharmacology and CNS drug discovery. Br J Pharmacol 174(13):1925–1944. https://doi.org/10.1111/bph.13754 CrossRefPubMedPubMedCentralGoogle Scholar
- 9.Yun-Zhu P, Liang L, Ai-Ling F, Yan L, Lan S, Qian L, Dan W, Man-Ji S, Ying-Ge Z, Bao-Quan Z (2017) Generation of alzheimer’s disease transgenic zebrafish expressing human APP mutation under control of zebrafish appb promotor. Curr Alzheimer Res 14(6):668–679. https://doi.org/10.2174/1567205013666161201202000 CrossRefGoogle Scholar
- 12.Marcon M, Herrmann AP, Mocelin R, Rambo CL, Koakoski G, Abreu MS, Conterato GMM, Kist LW, Bogo MR, Zanatta L, Barcellos LJG, Piato AL (2016) Prevention of unpredictable chronic stress-related phenomena in zebrafish exposed to bromazepam, fluoxetine and nortriptyline. Psychopharmacology 233(21):3815–3824. https://doi.org/10.1007/s00213-016-4408-5 CrossRefPubMedGoogle Scholar
- 18.Breedlove SM, Watson NV, Rosenzweig MR (2010) Biological psychology: an introduction to behavioral, cognitive, and clinical neuroscience. 6th edn, Sinauer Associates, Inc., SunderlandGoogle Scholar
- 21.Arnould-taylor WE (1998) A textbook of anatomy and physiology. 3rd edn, Stanley Thornes, Ltd., CheltenhamGoogle Scholar
- 23.Bahi-Buisson N, Nectoux J, Rosas-Vargas H, Milh M, Boddaert N, Girard B, Cances C, Ville D, Afenjar A, Rio M, Héron D, N’Guyen Morel MA, Arzimanoglou A, Philippe C, Jonveaux P, Chelly J, Bienvenu T (2008) Key clinical features to identify girls with CDKL5 mutations. Brain 131(10):2647–2661. https://doi.org/10.1093/brain/awn197 CrossRefPubMedGoogle Scholar
- 25.Evans JC, Archer HL, Colley JP, Ravn K, Nielsen JB, Kerr A, Williams E, Christodoulou J, Gécz J, Jardine PE, Wright MJ, Pilz DT, Lazarou L, Cooper DN, Sampson JR, Butler R, Whatley SD, Clarke AJ (2005) Early onset seizures and Rett-like features associated with mutations in CDKL5. Eur J Hum Genet 13:1113. https://doi.org/10.1038/sj.ejhg.5201451. https://www.nature.com/articles/5201451#supplementary-information
- 27.Archer HL, Evans J, Edwards S, Colley J, Newbury-Ecob R, O’Callaghan F, Huyton M, O’Regan M, Tolmie J, Sampson J, Clarke A, Osborne J (2006) CDKL5 mutations cause infantile spasms, early onset seizures, and severe mental retardation in female patients. J Med Genet 43(9):729–734. https://doi.org/10.1136/jmg.2006.041467 CrossRefPubMedPubMedCentralGoogle Scholar